3,890 reports of this reaction
1.4% of all ADALIMUMAB FKJP reports
#10 most reported adverse reaction
SYSTEMIC LUPUS ERYTHEMATOSUS is the #10 most commonly reported adverse reaction for ADALIMUMAB FKJP, manufactured by Biocon Biologics Inc. There are 3,890 FDA adverse event reports linking ADALIMUMAB FKJP to SYSTEMIC LUPUS ERYTHEMATOSUS. This represents approximately 1.4% of all 281,217 adverse event reports for this drug.
Patients taking ADALIMUMAB FKJP who experience systemic lupus erythematosus should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SYSTEMIC LUPUS ERYTHEMATOSUS is a less commonly reported adverse event for ADALIMUMAB FKJP, but still significant enough to appear in the safety profile.
In addition to systemic lupus erythematosus, the following adverse reactions have been reported for ADALIMUMAB FKJP:
The following drugs have also been linked to systemic lupus erythematosus in FDA adverse event reports:
SYSTEMIC LUPUS ERYTHEMATOSUS has been reported as an adverse event in 3,890 FDA reports for ADALIMUMAB FKJP. This does not prove causation, but indicates an association observed in post-market surveillance data.
SYSTEMIC LUPUS ERYTHEMATOSUS accounts for approximately 1.4% of all adverse event reports for ADALIMUMAB FKJP, making it a notable side effect.
If you experience systemic lupus erythematosus while taking ADALIMUMAB FKJP, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.